These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38639689)

  • 21. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials.
    Ziada KM; Abdel-Latif AK; Charnigo R; Moliterno DJ
    Catheter Cardiovasc Interv; 2016 Mar; 87(4):722-732. PubMed ID: 26309050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P2Y12 inhibitors in acute coronary syndrome: when to give them and when to prolong their use.
    Grotti S; Bolognese L
    J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e9-e12. PubMed ID: 29538137
    [No Abstract]   [Full Text] [Related]  

  • 23. Meta-analysis of duration of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention.
    Khan SU; Riaz IB; Rahman H; Lone AN; Raza M; Khan MS; Riaz A; Kaluski E
    Eur J Prev Cardiol; 2019 Mar; 26(4):429-432. PubMed ID: 30152256
    [No Abstract]   [Full Text] [Related]  

  • 24. Benefits of short-term or prolonged as compared to standard 1 year DAPT in patients with acute coronary syndrome treated with drug-eluting stents: a meta-analysis of 9 randomized trials.
    Verdoia M; Kedhi E; Suryapranata H; Frati G; Biondi-Zoccai G; De Luca G
    J Thromb Thrombolysis; 2020 Aug; 50(2):337-354. PubMed ID: 31919736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention.
    Luo L; Fu M; Li Y; Chen Z; Yu J; Luo J; Hu S; Tu L; Xu X
    Clin Cardiol; 2020 Mar; 43(3):235-241. PubMed ID: 31777973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
    Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
    Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of short-term dual antiplatelet therapy (≤6 months) after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis of randomized controlled trials.
    Misumida N; Abo-Aly M; Kim SM; Ogunbayo GO; Abdel-Latif A; Ziada KM
    Clin Cardiol; 2018 Nov; 41(11):1455-1462. PubMed ID: 30225978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioresorbable vascular scaffolds: Time to absorb past lessons or fade away?
    de Pommereau A; de Hemptinne Q; Varenne O; Picard F
    Arch Cardiovasc Dis; 2018 Apr; 111(4):229-232. PubMed ID: 29678390
    [No Abstract]   [Full Text] [Related]  

  • 29. Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial.
    Lee JM; Jung JH; Park KW; Shin ES; Oh SK; Bae JW; Rhew JY; Lee N; Kim DB; Kim U; Han JK; Lee SE; Yang HM; Kang HJ; Koo BK; Kim S; Cho YK; Shin WY; Lim YH; Rha SW; Kim SY; Lee SY; Kim YD; Chae IH; Cha KS; Kim HS
    Trials; 2015 Sep; 16():409. PubMed ID: 26374625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of individualized antiplatelet therapy for patients of acute coronary syndrome after percutaneous coronary intervention under the guidance of platelet function: A one-center retrospective cohort study.
    Dang W; Wang J; Zhang Q; Liu N; Li W; Yao Z
    Medicine (Baltimore); 2021 Apr; 100(16):e25601. PubMed ID: 33879725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antithrombotic treatment in anticoagulated atrial fibrillation patients undergoing percutaneous coronary intervention.
    Dézsi CA; Dézsi BB; Dézsi DA
    Eur J Intern Med; 2017 May; 40():1-7. PubMed ID: 28065663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rethinking Aspirin: Ditching the Daily "Pill"ar of Tradition.
    Finocchiaro S; Capodanno D
    JACC Cardiovasc Interv; 2024 May; 17(10):1246-1251. PubMed ID: 38811106
    [No Abstract]   [Full Text] [Related]  

  • 33. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
    Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aspirin-Free Strategies After Complex PCI: Type of P2Y
    Gragnano F; Calabrò P
    JACC Cardiovasc Interv; 2024 May; 17(9):1131-1133. PubMed ID: 38749593
    [No Abstract]   [Full Text] [Related]  

  • 35. Platelet Inhibition in Acute Coronary Syndrome and Percutaneous Coronary Intervention: Insights from the Past and Present.
    Gorog DA; Geisler T
    Thromb Haemost; 2020 Apr; 120(4):565-578. PubMed ID: 32074647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Very short dual antiplatelet therapy after PCI and new DES: a meta-analysis of 5 randomized trials.
    Verdoia M; Khedi E; Suryapranata H; De Luca G
    Rev Esp Cardiol (Engl Ed); 2021 Feb; 74(2):140-148. PubMed ID: 32482558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive Outcomes Evaluation After Percutaneous Coronary Intervention in Stable Ischemic Heart Disease and Acute Coronary Syndrome for Short- Versus Standard-Term Dual Antiplatelet Therapy: A Systematic Review and Meta-analysis of Randomized Control Trials.
    Bhattarai M; Ibrahim AM; Salih M; Tandan N; Al-Akchar M; Ayan M; Kulkarni A; Hafiz AM
    J Cardiovasc Pharmacol; 2020 Nov; 76(5):574-583. PubMed ID: 33165135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation.
    Godino C; Pivato CA; Rubino C; Russi A; Cera M; Margonato A
    Am J Cardiol; 2020 Aug; 129():122-124. PubMed ID: 32540165
    [No Abstract]   [Full Text] [Related]  

  • 39. Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention.
    Olivier CB; Bhatt DL; Leonardi S; Stone GW; Gibson CM; Steg PG; Hamm CW; Wilson MD; Mangum S; Price MJ; Prats J; White HD; Lopes RD; Harrington RA; Mahaffey KW;
    Circ Cardiovasc Interv; 2019 Jul; 12(7):e007342. PubMed ID: 31296081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sex-based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: three year results from the HORIZONS-AMI trial.
    Yu J; Mehran R; Grinfeld L; Xu K; Nikolsky E; Brodie BR; Witzenbichler B; Kornowski R; Dangas GD; Lansky AJ; Stone GW
    Catheter Cardiovasc Interv; 2015 Feb; 85(3):359-68. PubMed ID: 25115966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.